Pub Date : 2025-12-05DOI: 10.1038/s41408-025-01412-8
Mazyar Shadman, Jennifer S Harper, Alex Bokun, Chang Xu, Pei Lin, Gloria Graf, Xiaoxiao Lu
Treatment options for diffuse large B-cell lymphoma (DLBCL) have expanded, but real-world data on treatment patterns and outcomes remain limited. This study examined real-world outcomes in DLBCL patients treated between 10/1/2015 and 6/30/2024. Patients were stratified by lines of therapy (LOT) and treatments (1L rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]; 2L stem cell transplant [SCT]; and chimeric antigen receptor T-cell [CAR T] therapy (any LOT). Variables were reported descriptively. Time-to-event outcomes were assessed using the Kaplan-Meier method. LOT data from 9875 patients were included. R-CHOP-based regimens were the most common 1L treatment (61.7%-67.3% in 2016-2023; 49.4% in 2024). Conventional chemoimmunotherapy use decreased in 2L (81.6% in 2016 to 41.9% in 2024) and 3L (47.6% in 2016 to 22.1% in 2024), while novel therapies increased (43.0% in 2L and 55.9% in 3L in 2024). Median overall survival declined across LOT (1L: 58.1 months; 2L: 30.0 months), as did median time to next treatment (1L: 36.1 months; 2L: 10.6 months). Twelve-month treatment failure rates were 36.0% after 1L, 51.8% after 2L, and 42.2% after CAR T. Among CAR T recipients, 93 received one of 36 distinct subsequent regimens, indicating no standard of care. These findings highlight the unmet needs in DLBCL.
{"title":"Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database.","authors":"Mazyar Shadman, Jennifer S Harper, Alex Bokun, Chang Xu, Pei Lin, Gloria Graf, Xiaoxiao Lu","doi":"10.1038/s41408-025-01412-8","DOIUrl":"10.1038/s41408-025-01412-8","url":null,"abstract":"<p><p>Treatment options for diffuse large B-cell lymphoma (DLBCL) have expanded, but real-world data on treatment patterns and outcomes remain limited. This study examined real-world outcomes in DLBCL patients treated between 10/1/2015 and 6/30/2024. Patients were stratified by lines of therapy (LOT) and treatments (1L rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]; 2L stem cell transplant [SCT]; and chimeric antigen receptor T-cell [CAR T] therapy (any LOT). Variables were reported descriptively. Time-to-event outcomes were assessed using the Kaplan-Meier method. LOT data from 9875 patients were included. R-CHOP-based regimens were the most common 1L treatment (61.7%-67.3% in 2016-2023; 49.4% in 2024). Conventional chemoimmunotherapy use decreased in 2L (81.6% in 2016 to 41.9% in 2024) and 3L (47.6% in 2016 to 22.1% in 2024), while novel therapies increased (43.0% in 2L and 55.9% in 3L in 2024). Median overall survival declined across LOT (1L: 58.1 months; 2L: 30.0 months), as did median time to next treatment (1L: 36.1 months; 2L: 10.6 months). Twelve-month treatment failure rates were 36.0% after 1L, 51.8% after 2L, and 42.2% after CAR T. Among CAR T recipients, 93 received one of 36 distinct subsequent regimens, indicating no standard of care. These findings highlight the unmet needs in DLBCL.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":" ","pages":"14"},"PeriodicalIF":11.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12804711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1038/s41408-025-01411-9
Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar
{"title":"Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma","authors":"Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar","doi":"10.1038/s41408-025-01411-9","DOIUrl":"https://doi.org/10.1038/s41408-025-01411-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"29 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-03DOI: 10.1038/s41408-025-01415-5
Karan L Chohan,Lorenzo Gensini,Sherif Seif,Xiaowen Sun,Lei Feng,Melody R Becnel,Mahmoud M Gaballa,Hans C Lee,Oren Pasvolsky,Krina K Patel,J Christine Ye,Donna M Weber,Robert Z Orlowski,Sheeba K Thomas
{"title":"Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.","authors":"Karan L Chohan,Lorenzo Gensini,Sherif Seif,Xiaowen Sun,Lei Feng,Melody R Becnel,Mahmoud M Gaballa,Hans C Lee,Oren Pasvolsky,Krina K Patel,J Christine Ye,Donna M Weber,Robert Z Orlowski,Sheeba K Thomas","doi":"10.1038/s41408-025-01415-5","DOIUrl":"https://doi.org/10.1038/s41408-025-01415-5","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"3 1","pages":"211"},"PeriodicalIF":12.8,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Autoimmune diseases (AIDs) are associated with an increased risk of lymphoma. Although treatment strategies have changed substantially in AIDs, recent evidence regarding this association is lacking. Particularly, the impact of novel immunosuppressive/immunomodulatory agents and the cumulative effect of multiple medication use on lymphoma risk have not been well investigated. To address these, we used the LIFE Study database, which contains health care claims data from 2014 to 2023 in 15 municipalities in Japan. Of 2,229,423 individuals, 211,592 had AIDs and 530 subsequently developed lymphoma. Overall, AID cases had a significantly higher incidence of lymphoma than non-AID cases (hazard ratio [HR] 1.9). Among 23 AIDs, lymphoma risk was significantly elevated in 14, including Takayasu arteritis (6.6) and adult-onset Still's disease (4.7). Among immunosuppressive/immunomodulatory agents, calcineurin inhibitors, iguratimod, or methotrexate were associated with higher lymphoma risks. Importantly, the use of two or more medications strongly increased lymphoma risk (HR 2.7) in AID cases. Lymphoma subtype-specific analysis revealed novel associations, including T/NK-cell lymphoma in systemic lupus erythematosus. Our large-scale cohort study reveals an increased risk of lymphoma in AID patients, particularly those receiving multiple immunosuppressants/immunomodulators, underscoring the need for careful monitoring in these patients.
{"title":"Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study.","authors":"Ami Inokuchi,Haryoon Kim,Masatoshi Sakurai,Kyoko Masuda,Kota Mizuno,Yuya Koda,Eri Matsuki,Yasunori Kogure,Shoko Ukita,Megumi Maeda,Futoshi Oda,Yuko Kaneko,Yasunori Sato,Haruhisa Fukuda,Keisuke Kataoka","doi":"10.1038/s41408-025-01422-6","DOIUrl":"https://doi.org/10.1038/s41408-025-01422-6","url":null,"abstract":"Autoimmune diseases (AIDs) are associated with an increased risk of lymphoma. Although treatment strategies have changed substantially in AIDs, recent evidence regarding this association is lacking. Particularly, the impact of novel immunosuppressive/immunomodulatory agents and the cumulative effect of multiple medication use on lymphoma risk have not been well investigated. To address these, we used the LIFE Study database, which contains health care claims data from 2014 to 2023 in 15 municipalities in Japan. Of 2,229,423 individuals, 211,592 had AIDs and 530 subsequently developed lymphoma. Overall, AID cases had a significantly higher incidence of lymphoma than non-AID cases (hazard ratio [HR] 1.9). Among 23 AIDs, lymphoma risk was significantly elevated in 14, including Takayasu arteritis (6.6) and adult-onset Still's disease (4.7). Among immunosuppressive/immunomodulatory agents, calcineurin inhibitors, iguratimod, or methotrexate were associated with higher lymphoma risks. Importantly, the use of two or more medications strongly increased lymphoma risk (HR 2.7) in AID cases. Lymphoma subtype-specific analysis revealed novel associations, including T/NK-cell lymphoma in systemic lupus erythematosus. Our large-scale cohort study reveals an increased risk of lymphoma in AID patients, particularly those receiving multiple immunosuppressants/immunomodulators, underscoring the need for careful monitoring in these patients.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"107 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145657070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-28DOI: 10.1038/s41408-025-01414-6
Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Oren Pasvolsky, Mariola A. Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James A. Davis, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma S. Rana, Kelley Julian, Faiz Anwer, Leyla Shune, Shaun DeJarnette, Ariel F. Grajales-Cruz, Evguenia Ouchveridze, Gabriel De Avila, Sandra P. Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Erin Eberwein, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Joseph P. McGuirk, Adriana Rossi, Megan M. Herr, Omar Castaneda, Frederick L. Locke, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas W. Sborov, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP ( p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP ( p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP ( p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.
{"title":"The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience","authors":"Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Oren Pasvolsky, Mariola A. Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James A. Davis, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma S. Rana, Kelley Julian, Faiz Anwer, Leyla Shune, Shaun DeJarnette, Ariel F. Grajales-Cruz, Evguenia Ouchveridze, Gabriel De Avila, Sandra P. Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Erin Eberwein, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Joseph P. McGuirk, Adriana Rossi, Megan M. Herr, Omar Castaneda, Frederick L. Locke, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas W. Sborov, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee","doi":"10.1038/s41408-025-01414-6","DOIUrl":"https://doi.org/10.1038/s41408-025-01414-6","url":null,"abstract":"Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP ( <jats:italic>p</jats:italic> < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP ( <jats:italic>p</jats:italic> < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP ( <jats:italic>p</jats:italic> = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"19 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145611321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-27DOI: 10.1038/s41408-025-01427-1
Chenguang Wang, Suhaib Abdelrahman, Xiangrong Geng, Alyssa Burgess, Ying S. Hu, Mohd Ahmar Rauf, Nermin Kady, Yao Fu, Tara A. Reilly, Ira P. Maine, Phillip Boonstra, Kirill Sabitov, Carlos Murga-Zamalloa, Ryan A. Wilcox
The transcription factor GATA-binding protein 3 (GATA-3) regulates oncogenic transcriptional programs across diverse T-cell lymphomas, including subsets of both peripheral and primary cutaneous T-cell lymphomas. These GATA-3 dependent transcriptional programs, in collaboration with the genetic landscape, promote cell growth and survival, and confer resistance to conventional chemotherapeutic agents. We observed that transcriptional cyclin dependent kinase 9 (CDK9) activation regulates diverse oncogenic transcriptional programs in these aggressive T-cell lymphomas and is thus a novel therapeutic vulnerability. Using complementary and orthogonal approaches, we identified multiple independent mechanisms by which CDK9 promotes T-cell lymphomagenesis, including a mechanism by which GATA-3 promotes CDK9 activation at GATA-3 dependent loci. We also identify novel mechanisms by which GATA-3 and CDK9 regulate rRNA transcription and processing, respectively, collaboratively promoting ribosome biogenesis. Therefore, CDK9 is a therapeutic vulnerability across genetically and transcriptionally diverse T-cell lymphomas, including those for which GATA-3 is oncogenic.
{"title":"CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas","authors":"Chenguang Wang, Suhaib Abdelrahman, Xiangrong Geng, Alyssa Burgess, Ying S. Hu, Mohd Ahmar Rauf, Nermin Kady, Yao Fu, Tara A. Reilly, Ira P. Maine, Phillip Boonstra, Kirill Sabitov, Carlos Murga-Zamalloa, Ryan A. Wilcox","doi":"10.1038/s41408-025-01427-1","DOIUrl":"https://doi.org/10.1038/s41408-025-01427-1","url":null,"abstract":"The transcription factor GATA-binding protein 3 (GATA-3) regulates oncogenic transcriptional programs across diverse T-cell lymphomas, including subsets of both peripheral and primary cutaneous T-cell lymphomas. These GATA-3 dependent transcriptional programs, in collaboration with the genetic landscape, promote cell growth and survival, and confer resistance to conventional chemotherapeutic agents. We observed that transcriptional cyclin dependent kinase 9 (CDK9) activation regulates diverse oncogenic transcriptional programs in these aggressive T-cell lymphomas and is thus a novel therapeutic vulnerability. Using complementary and orthogonal approaches, we identified multiple independent mechanisms by which CDK9 promotes T-cell lymphomagenesis, including a mechanism by which GATA-3 promotes CDK9 activation at GATA-3 dependent loci. We also identify novel mechanisms by which GATA-3 and CDK9 regulate rRNA transcription and processing, respectively, collaboratively promoting ribosome biogenesis. Therefore, CDK9 is a therapeutic vulnerability across genetically and transcriptionally diverse T-cell lymphomas, including those for which GATA-3 is oncogenic.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"206 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145611323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-27DOI: 10.1038/s41408-025-01420-8
Lockwood Taylor, Angela Chen, Amy Pierre
{"title":"Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies","authors":"Lockwood Taylor, Angela Chen, Amy Pierre","doi":"10.1038/s41408-025-01420-8","DOIUrl":"https://doi.org/10.1038/s41408-025-01420-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"119 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145609160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1038/s41408-025-01410-w
Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, Jordan M. Schecter, Nikoletta Lendvai, Kevin C. De Braganca, Ana Slaughter, Carolina Lonardi, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Hao Zhao, Katherine Li, Erin Lee, Loreta Marquez, Man Zhao, Tzu-min Yeh, Diana Chen, Vicki Plaks, Rocio Montes de Oca, Erika Florendo, Nitin Patel, Muhammad Akram, Mythili Koneru, Bianca D. Santomasso, Jaime Gállego Perez-Larraya, Niels WCJ van de Donk
{"title":"Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4","authors":"Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, Jordan M. Schecter, Nikoletta Lendvai, Kevin C. De Braganca, Ana Slaughter, Carolina Lonardi, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Hao Zhao, Katherine Li, Erin Lee, Loreta Marquez, Man Zhao, Tzu-min Yeh, Diana Chen, Vicki Plaks, Rocio Montes de Oca, Erika Florendo, Nitin Patel, Muhammad Akram, Mythili Koneru, Bianca D. Santomasso, Jaime Gállego Perez-Larraya, Niels WCJ van de Donk","doi":"10.1038/s41408-025-01410-w","DOIUrl":"https://doi.org/10.1038/s41408-025-01410-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"145 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145599068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号